LDS/Medical Tests/Barrett's-Associated Neoplasia, FISH

Barrett's-Associated Neoplasia, FISH

Barrett’s esophagus (BE) is a premalignant condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by columnar epithelium, most often as a consequence of chronic gastroesophageal reflux disease (GERD). It predominantly affects middle-aged to older adults and is more common in males, individuals with central obesity, tobacco use, and chronic GERD. BE is clinically significant because it represents the principal precursor lesion to esophageal adenocarcinoma (EAC), an aggressive cancer with poor prognosis and increasing incidence in Western countries. The diagnosis of BE requires endoscopic identification of salmon-colored, columnar-lined mucosa extending above the gastroesophageal junction, confirmed by histologic evidence of intestinal metaplasia characterized by goblet cells. Debate exists over whether intestinal metaplasia is required for diagnosis, as some guidelines accept any columnar epithelium with gastric-type mucosa in the distal esophagus. Dysplasia, when present, is the best-established histologic predictor of malignant transformation, but its interpretation can be challenging due to interobserver variability, reactive changes, and sampling error.

Progression to cancer typically follows a metaplasia–low-grade dysplasia–high-grade dysplasia–adenocarcinoma sequence. Patients with high-grade dysplasia or early intramucosal carcinoma are typically managed with endoscopic resection and/or ablation rather than esophagectomy. However, histopathologic evaluation alone may be insufficient to accurately assess progression risk. Molecular markers and chromosomal abnormalities provide valuable complementary information.

Fluorescence in situ hybridization (FISH) has emerged as an effective molecular adjunct for BE evaluation. This assay utilizes fluorescently labeled DNA probes targeting specific chromosomal loci associated with genomic instability in BE and EAC. Commonly assessed loci include 8q24 (MYC), 9p21 (CDKN2A), 17q12 (ERBB2), and 20q13.2 (ZNF217). Detection of chromosomal polysomy, loss of 9p21, or gene amplification events is associated with increased risk of progression to high-grade dysplasia or adenocarcinoma. FISH complements histology by improving diagnostic accuracy in equivocal or indefinite-for-dysplasia cases, supporting molecular risk stratification, and guiding surveillance and therapeutic decision-making.

  • As an aid in the early detection and management of Barrett's esophagus and esophageal adenocarcinoma
  • Guides management decisions, including surveillance intervals and eligibility for endoscopic therapy
  • Adjunctive diagnostic tool when histology is indeterminate (e.g., indefinite for dysplasia, reactive atypia, or treatment-related changes)
A positive (abnormal) FISH result indicates the presence of chromosomal abnormalities such as polysomy, gene amplification, or 9p21 loss. These findings suggest genomic instability and a higher risk of progression to high-grade dysplasia or adenocarcinoma. Patients with abnormal FISH results should undergo closer endoscopic surveillance or be evaluated for endoscopic therapy. A negative (normal) FISH result indicates no significant chromosomal abnormalities detected. This finding is associated with a lower short-term risk of progression; however, it does not exclude the presence of dysplasia. Correlation with histopathologic and endoscopic findings remains essential for comprehensive risk assessment.

Normal cytogenetic profile

Fluorescence in situ hybridization (FISH) using multicolor locus-specific DNA probes.

Specimen Types: Esophageal cytology brushings (preferred), Esophageal or gastroesophageal junction biopsy tissue (FFPE)

Requirements: Cytology sample in appropriate fixative or transport medium. For FFPE tissue: provide 1–2 unstained slides (4–5 µm) and an H&E slide.

Stability

 

  • Room temperature: stable in fixative
  • FFPE blocks: stable long-term
  • Frozen samples: not acceptable
EsoGuard Methylation Assay for Barrett’s esophagus, esophageal biopsy, Barrett’s-associated neoplasia cytology, CBC with differential, comprehensive metabolic panel, HER2/neu (ERBB2) gene amplification by FISH.
5 to 10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login